Mixed Dyslipidemia

PHILADELPHIA — Three phase 2 trials, two of apolipoprotein C-III inhibition and one of angiopoietin-like protein 3 inhibition, demonstrated the efficacy and safety of dyslipidemia treatment via RNA interference.

CHICAGO — In the PROMINENT trial, pemafibrate lowered triglycerides but did not cut the incidence of CV events compared with placebo in patients with type 2 diabetes and mixed dyslipidemia.

Healio and Cardiology Today present the top-read articles published in January 2020. Healio readers were most interested in the impact of green tea on ASCVD, contributors to losing the battle against heart disease, the ability of positive ECG and negative echocardiography identify patients with elevated CV risk, the use of marijuana in patients with CVD and more.

AstraZeneca announced that it will close the STRENGTH CV outcomes trial of omega-3 carboxylic acids in patients with mixed dyslipidemia at high risk for CVD.